SHANDONG XINHUA (00719) has announced that it recently obtained the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. In August 2024, the company submitted the application materials for the market approval registration of the capsules to the Center for Drug Evaluation (CDE) of the NMPA, which were accepted. The registration certificate was granted in February 2026, with the review conclusion being approval for registration. This product is clinically indicated for the treatment of primary and secondary osteoarthritis. It is classified as a Category B drug in the National Reimbursement Drug List for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (2025). According to relevant statistics, the sales of Glucosamine Sulfate Capsules in Chinese public medical institutions reached approximately RMB 850 million in 2024.